Loading...
Loading...
Isis Pharmaceuticals, Inc.
announced the initiation of a Phase 2 study of ISIS-SMN[Rx] in
infants with spinal muscular atrophy (SMA). SMA is a severe and rare genetic
neuromuscular disease characterized by muscle atrophy and weakness and is the
most common genetic cause of infant mortality. The study, which will begin
enrolling patients soon, is a Phase 2 study in eight patients with
infantile-onset SMA. The study, which initiates the Phase 2/3 program for
ISIS-SMN[Rx] in infants, is designed to provide data to allow Isis to define
the optimal dose for the larger planned Phase 2/3 study in infants and to
provide safety and tolerability data. Isis will earn a $3.5 million milestone
payment from Biogen Idec when the first infant is dosed in the study, which is
projected for May 2013.
The Phase 2 study of ISIS-SMN[Rx] is an open-label, multiple-dose,
dose-escalation pilot study, which will include eight infants who have been
diagnosed with SMA. To meet enrollment criteria, infants must be between the
ages of three weeks and seven months, live in close proximity to a study site
and pass screening evaluations conducted at study sites. The study will be
conducted at centers in the United States and Canada. For further study
information, please visit www.clinicaltrials.gov and search for ISIS-SMN[Rx].
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in